{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:08Z","timestamp":1793134088075,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Drug-induced xerostomia significantly affects quality of life. This study evaluated subjective and objective oral dryness in 101 patients with overactive bladder (OAB) receiving solifenacin (5 or 10\u00a0mg) or mirabegron (50\u00a0mg). Fox and Xerostomia Inventory questionnaires assessed subjective xerostomia, while unstimulated salivary flow measured objective changes. Overall, salivary flow declined from 0.35 to 0.27\u00a0ml\/min (\u2212\u200915.1%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with the greatest reduction in the solifenacin 10\u00a0mg group (\u2212\u200919.3%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Mirabegron had a minimal, non-significant impact (\u2212\u20095.9%; <jats:italic>p<\/jats:italic>\u2009=\u20090.42). Hyposalivation prevalence rose from 12.9% pre-treatment to 25.7% post-therapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), especially among solifenacin users. Men had higher baseline salivation (0.45 vs. 0.27\u00a0ml\/min; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), though both sexes experienced comparable proportional decreases. Mirabegron in multivariable analysis markedly reduced the risk of hyposalivation (OR 0.12, 95% CI 0.02\u20130.90), whereas hypertension increased it six-fold (OR 6.13, 95% CI 1.02\u201336.78); each additional 0.1\u00a0mL of baseline saliva independently decreased the odds (OR 0.32, 95% CI 0.27\u20130.38). These findings underscore the need for collaboration among urologists, dentists, and otolaryngologists to identify high-risk individuals early and implement preventive strategies. Adjusting OAB pharmacotherapy regimens may help optimize treatment efficacy while minimizing xerostomia\u2019s detrimental impact on oral health and patient quality of life.<\/jats:p>","DOI":"10.1038\/s41598-025-09720-6","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:55:56Z","timestamp":1752137756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug-induced xerostomia and hyposalivation in patients with overactive bladder: a prospective open-label observational study comparing antimuscarinics and \u03b23-adrenoceptor agonists"],"prefix":"10.1038","volume":"15","author":[{"given":"Magdalena","family":"Ostrowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Settaf-Cherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kiersztyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz A.","family":"Drewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Adamowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej J.","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"9720_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/dj12020030","volume":"12","author":"MS Lipsky","year":"2024","unstructured":"Lipsky, M. S., Singh, T., Zakeri, G. & Hung, M. Oral health and older adults: A narrative review. Dent. J. 12, 1\u201314 (2024).","journal-title":"Dent. J."},{"key":"9720_CR2","first-page":"500","volume":"19","author":"H Sharif","year":"2024","unstructured":"Sharif, H. et al. Evaluation of oral health among people with Multimorbidity in the marginalized population of karachi, pakistan: A multicenter cross-sectional study. J. Taibah Univ. Med. Sci. 19, 500\u2013515 (2024).","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"9720_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0030-4220(88)90268-X","volume":"66","author":"LM Sreebny","year":"1988","unstructured":"Sreebny, L. M. & Valdini, A. Xerostomia. Part I: Relationship to other oral symptoms and salivary gland hypofunction. Oral Surg. Oral Med. Oral Pathol. 66, 451\u2013458 (1988).","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"key":"9720_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejpb.2019.06.016","volume":"142","author":"E Roblegg","year":"2019","unstructured":"Roblegg, E., Coughran, A., Sirjani, D. & Saliva. An all-rounder of our body. Eur. J. Pharm. Biopharm. 142, 133\u2013141 (2019).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"9720_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/pharmacy9040162","volume":"9","author":"WM Thomson","year":"2021","unstructured":"Thomson, W. M., Smith, M. B., Ferguson, C. A. & Moses, G. The challenge of medication-induced dry mouth in residential aged care. Pharmacy 9, 162 (2021).","journal-title":"Pharmacy"},{"key":"9720_CR6","doi-asserted-by":"publisher","first-page":"e762","DOI":"10.4317\/medoral.24731","volume":"26","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2021","unstructured":"P\u00e9rez-Gonz\u00e1lez, A. et al. Association between xerostomia, oral and general health, and obesity in adults. A cross-sectional pilot study. Med. Oral Patol. Oral Y Cir. Bucal. 26, e762\u2013e769 (2021).","journal-title":"Med. Oral Patol. Oral Y Cir. Bucal"},{"key":"9720_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1590\/0103-6440201802302","volume":"29","author":"BA Agostini","year":"2018","unstructured":"Agostini, B. A. et al. How common is dry mouth? Systematic review and meta-regression analysis of prevalence estimates. Braz Dent. J. 29, 606\u2013618 (2018).","journal-title":"Braz Dent. J."},{"key":"9720_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40266-013-0141-5","volume":"31","author":"CT Nguyen","year":"2014","unstructured":"Nguyen, C. T., MacEntee, M. I., Mintzes, B. & Perry, T. L. Information for physicians and pharmacists about drugs that might cause dry mouth: A study of monographs and published literature. Drugs Aging. 31, 55\u201365 (2014).","journal-title":"Drugs Aging"},{"key":"9720_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11255-014-0892-x","volume":"47","author":"J Park","year":"2015","unstructured":"Park, J. et al. A prospective, observational study to assess the association between dry mouth and Solifenacin treatment in patients with overactive bladder syndrome. Int. Urol. Nephrol. 47, 235\u2013242 (2015).","journal-title":"Int. Urol. Nephrol."},{"key":"9720_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-76846-0","volume":"10","author":"M Przydacz","year":"2020","unstructured":"Przydacz, M., Golabek, T., Dudek, P., Lipinski, M. & Chlosta, P. Prevalence and bother of lower urinary tract symptoms and overactive bladder in poland, an Eastern European study. Sci. Rep. 10, 1\u201312 (2020).","journal-title":"Sci. Rep."},{"key":"9720_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin, D. E., Kopp, Z. S., Agatep, B., Milsom, I. & Abrams, P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 108, 1132\u20131138 (2011).","journal-title":"BJU Int."},{"key":"9720_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/luts.12481","volume":"15","author":"HX Chen","year":"2023","unstructured":"Chen, H. X. et al. Mirabegron is better tolerated than Solifenacin in sjogren\u2019s syndrome patients with overactive bladder symptoms-A randomized controlled trial. Low Urin Tract. Symptoms. 15, 139\u2013147 (2023).","journal-title":"Low Urin Tract. Symptoms"},{"key":"9720_CR13","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1007\/s00784-020-03276-7","volume":"24","author":"Z Assy","year":"2020","unstructured":"Assy, Z., Jager, D. H. J., Mashhour, E., Bikker, F. J. & Brand, H. S. Regional differences in perceived oral dryness as determined with a newly developed questionnaire, the regional oral dryness inventory. Clin. Oral Investig. 24, 4051\u20134060 (2020).","journal-title":"Clin. Oral Investig"},{"key":"9720_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0280224","volume":"18","author":"K Ito","year":"2023","unstructured":"Ito, K. et al. Characteristics of medication-induced Xerostomia and effect of treatment. PLoS One. 18, 1\u201314 (2023).","journal-title":"PLoS One"},{"key":"9720_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","volume":"48","author":"CR Chapple","year":"2005","unstructured":"Chapple, C. R. et al. A comparison of the efficacy and tolerability of Solifenacin succinate and extended release Tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur. Urol. 48, 464\u2013470 (2005).","journal-title":"Eur. Urol."},{"key":"9720_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","volume":"93","author":"CR Chapple","year":"2004","unstructured":"Chapple, C. R. et al. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent Solifenacin in patients with symptomatic overactive bladder. BJU Int. 93, 303\u2013310 (2004).","journal-title":"BJU Int."},{"key":"9720_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","volume":"4","author":"A Wagg","year":"2006","unstructured":"Wagg, A., Wyndaele, J. J. & Sieber, P. Efficacy and tolerability of Solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am. J. Geriatr. Pharmacother. 4, 14\u201324 (2006).","journal-title":"Am. J. Geriatr. Pharmacother"},{"key":"9720_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1590\/s1677-5538.ibju.2023.0158","volume":"49","author":"W He","year":"2023","unstructured":"He, W. et al. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: A systematic review and network meta-analysis. Int. Braz J. Urol. 49, 535\u2013563 (2023).","journal-title":"Int. Braz J. Urol."},{"key":"9720_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","volume":"82","author":"S Herschorn","year":"2013","unstructured":"Herschorn, S. et al. A phase iii, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82, 313\u2013320 (2013).","journal-title":"Urology"},{"key":"9720_CR20","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s00784-018-2393-2","volume":"22","author":"MS Bulthuis","year":"2018","unstructured":"Bulthuis, M. S., Jager, J., Brand, H. S. & D. H. & Relationship among perceived stress, xerostomia, and salivary flow rate in patients visiting a saliva clinic. Clin. Oral Investig. 22, 3121\u20133127 (2018).","journal-title":"Clin. Oral Investig"},{"key":"9720_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0282740","volume":"18","author":"I Morita","year":"2023","unstructured":"Morita, I. et al. Discordance between hyposalivation and Xerostomia among community-dwelling older adults in Japan. PLoS One. 18, 1\u20139 (2023).","journal-title":"PLoS One"},{"key":"9720_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jdent.2014.03.003","volume":"42","author":"S Hahnel","year":"2014","unstructured":"Hahnel, S., Schwarz, S., Zeman, F., Sch\u00e4fer, L. & Behr, M. Prevalence of Xerostomia and hyposalivation and their association with quality of life in elderly patients in dependence on dental status and prosthetic rehabilitation: A pilot study. J. Dent. 42, 664\u2013670 (2014).","journal-title":"J. Dent."},{"key":"9720_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1741-2358.2007.00137.x","volume":"24","author":"WM Thomson","year":"2007","unstructured":"Thomson, W. M. Measuring change in dry-mouth symptoms over time using the Xerostomia inventory. Gerodontology 24, 30\u201335 (2007).","journal-title":"Gerodontology"},{"key":"9720_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/ger.12497","volume":"37","author":"G Pina","year":"2020","unstructured":"Pina, G., de Carvalho, M. S. M., Silva, R., Almeida, F. T. & B. S. de F. & Prevalence of hyposalivation in older people: A systematic review and meta-analysis. Gerodontology 37, 317\u2013331 (2020).","journal-title":"Gerodontology"},{"key":"9720_CR25","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3390\/cancers14143379","volume":"14","author":"J Stolze","year":"2022","unstructured":"Stolze, J. et al. Prevalence and risk factors for hyposalivation and xerostomia in childhood cancer survivors following different treatment modalities\u2014A Dutch childhood cancer survivor study late effects 2 clinical study (DCCSS LATER 2). Cancers (Basel) 14, 3379 (2022).","journal-title":"Cancers (Basel)"},{"key":"9720_CR26","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jdent.2018.08.010","volume":"80","author":"AM Lynge Pedersen","year":"2019","unstructured":"Lynge Pedersen, A. M. & Belstr\u00f8m, D. The role of natural salivary defences in maintaining a healthy oral microbiota. J. Dent. 80, S3\u2013S12 (2019).","journal-title":"J. Dent."},{"key":"9720_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000454781","volume":"51","author":"O Paper","year":"2017","unstructured":"Paper, O. pH response and tooth surface solubility at the tooth \/ Bacteria interface. Caries Res. 51, 160\u2013166 (2017). https:\/\/doi.org\/10.1159\/000454781","journal-title":"Caries Res"},{"key":"9720_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/87551225221108599","volume":"38","author":"MP Krajewski","year":"2022","unstructured":"Krajewski, M. P. et al. Medication use among patients reporting Xerostomia of an academic dental clinic. J. Pharm. Technol. 38, 264\u2013271 (2022).","journal-title":"J. Pharm. Technol."},{"key":"9720_CR29","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T. & Giovannucci, E. L. Trends in prescription drug use among adults in the United States from 1999\u20132012. JAMA - J. Am. Med. Assoc. 314, 1818\u20131831 (2015).","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"9720_CR30","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1111\/adj.12767","volume":"65","author":"LM Jamieson","year":"2020","unstructured":"Jamieson, L. M. & Thomson, W. M. Xerostomia: Its prevalence and associations in the adult Australian population. Aust Dent. J. 65, S67\u2013S70 (2020).","journal-title":"Aust Dent. J."},{"key":"9720_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-024-01617-x","author":"EM Dourieu","year":"2024","unstructured":"Dourieu, E. M. & Evans, W. Xerostomia: A silent burden for people receiving palliative care\u2014A qualitative descriptive study. BMC Palliat. Care. https:\/\/doi.org\/10.1186\/s12904-024-01617-x (2024).","journal-title":"BMC Palliat. Care"},{"key":"9720_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40266-023-01017-5","volume":"40","author":"I Cannon","year":"2023","unstructured":"Cannon, I., Robinson-Barella, A., McLellan, G. & Ramsay, S. E. From drugs to dry mouth: A systematic review exploring oral and psychological health conditions associated with dry mouth in older adults with polypharmacy. Drugs Aging. 40, 307\u2013316 (2023).","journal-title":"Drugs Aging"},{"key":"9720_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson, M. E., Carrozzino, D., Guidi, J. & Patierno, C. Charlson comorbidity index: A critical review of clinimetric properties. Psychother. Psychosom. 91, 8\u201335 (2022).","journal-title":"Psychother. Psychosom."},{"key":"9720_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/1807-3107bor-2017.vol31.0014","volume":"31","author":"S Niklander","year":"2017","unstructured":"Niklander, S. et al. Risk factors, hyposalivation and impact of Xerostomia on oral health-related quality of life. Braz Oral Res. 31, 1\u20139 (2017).","journal-title":"Braz Oral Res."},{"key":"9720_CR35","first-page":"190","volume":"21","author":"A Mohiti","year":"2020","unstructured":"Mohiti, A., Eslami, F. & Dehestani, M. R. Does hypertension affect saliva properties?? J. Dent. (Shiraz Iran). 21, 190\u2013194 (2020).","journal-title":"J. Dent. (Shiraz Iran)"},{"key":"9720_CR36","first-page":"e185","volume":"22","author":"RM L\u00f3pez-Pintor","year":"2017","unstructured":"L\u00f3pez-Pintor, R. M., L\u00f3pez-Pintor, L., Casa\u00f1as, E., de Arriba, L. & Hern\u00e1ndez, G. Risk factors associated with Xerostomia in haemodialysis patients. Med. Oral Patol. Oral Cir. Bucal. 22, e185\u2013e192 (2017).","journal-title":"Med. Oral Patol. Oral Cir. Bucal"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09720-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T03:23:41Z","timestamp":1757215421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09720-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9720"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09720-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent to participate was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"24758"}}